# A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease

> **NCT05529992** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 20 (actual)

## Conditions studied

- Gaucher Disease

## Interventions

- **DRUG:** Velaglucerase Alfa

## Key facts

- **NCT ID:** NCT05529992
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-03
- **Primary completion:** 2024-08-05
- **Final completion:** 2024-08-05
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05529992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05529992, "A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05529992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*